Skip to content
DataLookout
Menu

STRIKENCT06661720

Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer

StatusRecruiting
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 16 versions: 16 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 32 words
    • Trial sites expanded: 425 → 429 locations
    • Secondary endpoints: details revised at 3 of 3 entries
  2. Minor Trial sites expanded: 421 → 425 locationsv15
  3. Minor Trial sites expanded: 415 → 421 locationsv14
  4. Notable Eligibility criteria revised
    • Study sites: 414 to 415
    v13
  5. Minor Trial sites expanded: 410 → 414 locationsv12
  6. Minor Study sites: 409 to 410v11
  7. Minor Trial sites expanded: 399 → 409 locationsv10
  8. Minor Study sites: 393 to 399v9
  9. Minor Study sites: 373 to 393v8
  10. Minor Study sites: 371 to 373v7
  11. Minor Study sites: 361 to 371v6
  12. Minor Study sites: 301 to 361v5
  13. Minor Study sites: 208 to 301v4
  14. Minor Study sites: 62 to 208v3
  15. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Nov 7, 2024 to Mar 14, 2025
    • Study sites: 0 to 62
    v2
  16. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Disease-free survival (DFS)
Timeframe: From time of randomization until disease recurrence or death, assessed up to 10 years

Secondary (3)

Overall survival (OS)
Incidence of adverse events (AEs)
Proportion of patients that tolerate pembrolizumab and tivozanib

Arms and interventions

Arm 1 (Pembrolizumab)Active comparator

Patients receive pembrolizumab IV on days 1 and 43 of each cycle, or on days 1, 22, 43 and 64 of each cycle. Cycles repeat every 12 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo blood sample collection and MRI or CT throughout the trial and may undergo tissue biopsy on study.

Arm 2 (pembrolizumab + tivozanib)Experimental

Patients receive pembrolizumab IV on days 1 and 43 of each cycle and tivozanib PO QD on days 1-21, days 29-49, and days 57-77 of each cycle for up to 6 months. Cycles repeat every 12 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo blood sample collection and MRI or CT throughout the trial and may undergo tissue biopsy on study.

Biologicals: Pembrolizumab

Drugs: Tivozanib

Procedures: Biospecimen Collection, MRI, Computed Tomography, Biopsy

Other: Questionnaire Administration

Sites

429 sites in 1 country